Dose separation does not overcome the pharmacokinetic interaction between fosamprenavir and lopinavir/ritonavir

Antimicrobial Agents and Chemotherapy

Volumn 50, Issue 8, 2006, Pages 2756-2761

  Corbett, Amanda H ^a   Patterson, Kristine B ^b   Tien, Hsiao Chuan ^a   Kalvass, Leslie A ^a   Eron, Joseph J ^a,b   Ngo, Linh T ^b   Lim, Michael L ^c   Kashuba, Angela D M ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR PHOSPHATE; ANTIDIARRHEAL AGENT; ANTIHISTAMINIC AGENT; ATROPINE PLUS DIPHENOXYLATE; CLINDAMYCIN; LOPERAMIDE; LOPINAVIR PLUS RITONAVIR; MINOCYCLINE; RITONAVIR;

ADULT; AREA UNDER THE CURVE; ARTICLE; CALCULATION; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EXPOSURE; FEMALE; FOLLICULITIS; GASTROINTESTINAL SYMPTOM; GEOMETRIC MEAN RATIO; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LEUKOCYTOSIS; LOOSE FECES; MACULOPAPULAR RASH; MALE; MEASUREMENT; NAUSEA; NORMAL HUMAN; PARESTHESIA; PERIORAL PARESTHESIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; TANDEM MASS SPECTROMETRY; TIME; VOLUNTEER;

ADOLESCENT; ADULT; AREA UNDER CURVE; CARBAMATES; CLINICAL TRIALS; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FEMALE; HIV PROTEASE INHIBITORS; HIV SERONEGATIVITY; HUMANS; MALE; PHOSPHORIC ACID ESTERS; PYRIMIDINONES; RITONAVIR; SULFONAMIDES;

EID: 33746889087     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.01006-05     Document Type: Article

References (31)

1. Abbott Laboratories. February 2005. Product information for Kaletra. [Online.] http://www.rxabbott.com/pdf/kaletrapi.pdf.
2. AIDS Clinical Trials Group. AIDS Clinical Trials Group (ACTG) toxicity grading scale. AIDS Clinical Trials Group, Silver Spring, Md.
3. Allen, A., M. Vousden, A. Porter, and A. Lewis. 1999. Effect of Maalox on the bioavailability of oral gemifloxacin in healthy volunteers. Chemotherapy 45:504-511.
4. Bertz, R. G., C. Foit, E. Ashbrenner, D. Burt, L. A. Williams, T. Chira, B. Bernstein, R. Wieboldt, E. Tillmann, T. Heuser, R. Rode, A. Hsu, G. R. Granneman, and E. Sun. 2002. Effect of amprenavir on the steady-state pharmacokinetics of lopinavir/ritonavir in human immunodeficiency virus-positive and healthy subjects, abstr. A-1823. Program Abstr. 42nd Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, D.C.
5. Boffito, M., D. J. Back, T. F. Blaschke, M. Rowland, R. J. Bertz, J. G. Gerber, and V. Miller. 2003. Protein binding in antiretroviral therapies. AIDS Res. Hum. Retrovir. 19:825-835.
6. Corbett, A. H., J. J. Eron, S. A. Fiscus, N. L. Rezk, and A. D. Kashuba. 2004. The pharmacokinetics, safety, and initial virologie response of a triple-protease inhibitor salvage regimen containing amprenavir, saquinavir, and ritonavir. J. Acquir. Immune Defic. Syndr. 36:921-928.
7. GlaxoSmithKline. May 2004. Product information for Lexiva. [Online.] http: //us.gsk.com/products/assets/us_lexiva.pdf.
8. Gonzalez-Garcia, J. C.-S. A., B. Duque, J. R. Arribas, A. Soto, J. M. Pena, and J. Frias-Iniesta. 2002. Soft-gel saquinavir and lopinavir/ritonavir double boosted PI regimen: a pharmacokinetic study, abstr. B10398. Presented at the XIV International AIDS Conference, 7 to 12 July 2002.
9. Hammer, S. M., F. Vaida, K. K. Bennett, M. K. Holohan, L. Sheiner, J. J. Eron, L. J. Wheat, R. T. Mitsuyasu, R. M. Gulick, F. T. Valentine, J. A. Aberg, M. D. Rogers, C. N. Karol, A. J. Saah, R. H. Lewis, L. J. Bessen, C. Brosgart, V. DeGruttola, and J. W. Mellors. 2002. Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial. JAMA 288:169-180.
10. Handschin, C., and U. A. Meyer. 2003. Induction of drug metabolism: the role of nuclear receptors. Pharmacol. Rev. 55:649-673.
11. Hellinger, J., C. J. Cohen, A. B. Morris, S. Piscitelli, D. Gordon, K. Foy, L. Jackson-Pope, D. Cordeiro, M. Peeters, R. Hoetelmans, and P. J. de Caprariis. 2002. Pilot study of safety and antiviral activity of saquinavir 1000 mg twice daily and lopinavir/ritonavir (Kaletra) combination therapy in HIV positive individuals, abstr. 451-W. Presented at the 9th Conference on Retroviruses and Opportunistic Infections, 24 to 28 February 2002.
12. Ho, R. H., and R. B. Kim. 2005. Transporters and drug therapy: implications for drug disposition and disease. Clin. Pharmacol. Ther. 78:260-277.
13. Kashuba, A. D., C. Tierney, G. F. Downey, E. P. Acosta, E. N. Vergis, K. Klingman, J. W. Mellors, S. H. Eshleman, T. R. Scott, and A. C. Collier. 2005. Combining fosamprenavir with lopinavir/ritonavir substantially reduces amprenavir and lopinavir exposure: ACTG protocol A5143 results. AIDS 19:145-152.
14. Knupp, C. A., F. M. Graziano, R. M. Dixon, and R. H. Barbhaiya. 1992. Pharmacokinetic-interaction study of didanosine and ranitidine in patients seropositive for human immunodeficiency virus. Antimicrob. Agents Chemother. 36:2075-2079.
15. Kumar, G. N., J. Dykstra, E. M. Roberts, V. K. Jayanti, D. Hickman, J. Uchic, Y. Yao, B. Surber, S. Thomas, and G. R. Granneman. 1999. Potent inhibition of the cytochrome P-450 3A-mediated human liver microsomal metabolism of a novel HIV protease inhibitor by ritonavir: a positive drug-drug interaction. Drug Metab. Dispos. 27:902-908.
16. la Porte, C. J., J. C. Wasmuth, K. Schneider, J. K. Rockstroh, and D. M. Burger. 2003. Lopinavir/ritonavir plus saquinavir in salvage therapy; pharmacokinetics, tolerability and efficacy. AIDS 17:1700-1702.
17. Molla, A., H. Mo, S. Vasavanonda, L. Han, C. T. Lin, A. Hsu, and D. J. Kempf. 2002. In vitro antiviral interaction of lopinavir with other protease inhibitors. Antimicrob. Agents Chemother. 46:2249-2253.
18. Piscitelli, S. C., and K. D. Gallicano. 2001. Interactions among drugs for HIV and opportunistic infections. N. Engl. J. Med. 344:984-996.
19. Raguin, G., G. Chene, L. Morand-Joubert, A. M. Taburet, C. Droz, C. Le Tiec, F. Clavel, and P. M. Girard. 2004. Salvage therapy with amprenavir, lopinavir and ritonavir 200 mg/d or 400 mg/d in HIV-infectcd patients in virological failure. Antivir. Ther. 9:615-625.
20. Reynolds, H. E., S. E. Gibbons, J. F. Tjia, S. H. Khoo, and D. J. Back. 2002. The pharmacokinetic interaction of lopinavir/ritonavir and amprenavir in clinical practice, abstr. TuPeB4560. Presented at the XIV International AIDS Conference, 7 to 12 July 2002.
21. Ribera, E., M. Diaz, L. Pou, L. Ruiz, I. Ocana, and V. Falco. 2002. Steady-state pharmacokinetics of a double boosting regimen of lopinavir, plus minidose ritonavir, plus saquinavir soft-gel in HIV infected adults, abstr. TuPeB4545. Presented at the XIV International AIDS Conference, 7 to 12 July 2002.
22. Smith, G. H. R., M. B. Keine, T. Murphy, N. Gilmore, R. P. Leblanc, J. Macleod, P. Rene, J. P. Routy, and R. G. Lalonde. 2002. Double, boosted salvage therapy with lopinavir (LOP)/ritonavir (RIT) and saquinavir-sgc (SQR) in HIV-1 infected patients having failed 3 antiretroviral classes, abstr. TuPeB4547. Presented at the XIV International AIDS Conference, 7 to 12 July 2002.
23. Stass, H., M. F. Bottcher, and K. Ochmann. 2001. Evaluation of the influence of antacids and H2 antagonists on the absorption of moxifloxacin after oral administration of a 400mg dose to healthy volunteers. Clin. Pharmacokinet. 40(Suppl. 1):39-48.
24. Staszewski, S, B. Dauer, N. Von Hentig, A. Muller, C. Stephan, A. Carlebach, M. Mosch, P. Gute, S. Klauke, M. Kurowski, and M. Sturmer. 2003. The LOPSAQ study: 24 week analysis of double protease inhibitor (PI) salvage regimens containing lopinavir (LPV/r) plus saquinavir (SQV) without any additional antiretroviral (ART) therapy, abstr. 583. Presented at the 2nd International AIDS Conference on HIV Pathogenesis and Treatment, 13 to 16 July 2003.
25. Stephan, C., N. von Hentig, M. Moesch, A. Carlebach, M. Kurowski, S. Klauke, T. Lutz, and S. Staszewski. 2003. Pharmacokinetic comparison of single versus double boosted protease inhibitor regimen: effective saquinavir levels by coadministration with lopinavir/ritonavir, abstr. 1119. Presented at the 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, 13 to 16 July 2003.
26. Taburet, A. M., G. Raguin, C. Le Tiec, C. Droz, A. Barrail, I. Vincent, L. Morand-Joubert, G. Chene, F. Clavel, and P. M. Girard. 2004. Interactions between amprenavir and the lopinavir-ritonavir combination in heavily pretreated patients infected with human immunodeficiency virus. Clin. Pharmacol. Ther. 75:310-323.
27. Tran, J. Q., C. Petersen, M. Garrett, B. Hee, and B. M. Kerr. 2002. Pharmacokinetic interaction between amprenavir and delavirdine: evidence of induced clearance by amprenavir. Clin. Pharmacol. Ther. 72:615-626.
28. Washington, C. B., C. Flexner, L. B. Sheiner, S. L. Rosenkranz, Y. Segal, J. A. Aberg, and T. F. Blaschke. 2003. Effect of simultaneous versus staggered dosing on pharmacokinetic interactions of protease inhibitors. Clin. Pharmacol. Ther. 73:406-416.
29. Wire, M. B., O. J. Naderer, A. L. Masterman, Y. Lou, and D. S. Stein. 2004. The pharmacokinetic (PK) interaction between GW433908 (908) with lopinavir (LPV)/ritonavir (RTV) (APV10011 and APV10012), poster 612. Presented at the 11th Conference on Retroviruses and Opportunistic Infections, 8 to 11 February 2004.
30. Yeh, R. F., V. E. Gaver, J. J. Park, K. B. Patterson, N. Rezk, F. Baxter-Meheux, R. Bertz, J. J. Eron, and A. D. M. Kashuba. 2004. Lopinavir/ritonavir (Kaletra) induces CYP2C9 and 2C19 activity as measured by warfarin and omeprazole biomarkers in healthy human volunteers. Presented at the 5th International Workshop on Clinical Pharmacology of HIV Therapy, 1 to 3 April 2004.
31. Zala, C., P. Patterson, P. Coll, M. B. Bouzas, S. Kaufman, A. Gun, H. Perez, and P. Cahn. 2002. To evaluate early antiviral response and safety of a dual boosted protease inhibitor regimen including lopinavir/r (LPV) plus amprenavir (AMP) or fortovase (FTV) in heavily pretrcatcd HIV infected patients, abstr. TuPeB4492. Presented at the XIV International AIDS Conference, 7 to 12 July 2002.